Senior Writer, Europe
Eliza Slawther began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.
Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest From Eliza Slawther
MedTech Europe’s latest annual report unveils facts and figures that contextualize the European market against the global stage and highlight which countries are leading the way for medtech sales and employment.
Medtech companies will avoid the need to comply with yet another EU regulation, it seems, after the European Commission confirmed that proposals to tighten up cybersecurity rules for internet-connected products will not apply to medical devices.
Sweden is searching for innovative devices that patients can use at home as part of its latest horizon scanning project. Medtech Insight spoke to an expert about the latest developments in and fundamentals of Sweden’s medical device market access system.
It is vital to involve patients in medical device development, regulatory assessments, and post-marketing activities. The European Patients’ Academy on Therapeutic Innovation (EUPATI) has explained why and what it is doing to drive progress.
Detailed guidance documents aim to provide clarity on what constitutes “sufficient” clinical evidence under the new EU Medical Device Regulation. But a void remains between the MDR itself and what notified bodies expect, senior regulatory consultant Søren Underbjerg attests.
There is potential for ethnic and socio-economic bias in medical device design, funding allocation and regulatory guidelines, according to the UK’s Department of Health and Social Care (DHSC), which has commissioned a review to uncover the extent of the problem.